An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Financial toxicity is pervasive in rural oncology, with 53% reporting unaffordable care, 50% carrying medical debt, and 70% ...

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...

Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last ...

An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...